Recent Updates
Recently added Catalysts

V110, pneumococcal vaccine polyvalent

Phase 3

Healthy | Monoclonal antibody | Other |Merck & Company, Inc.|Last Updated: Jan 29, 2015

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindUNCONTROLLED
Total Trials1
Total Enrollment130
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00127153A Study of V110 a Pneumococcal Vaccine in Healthy Adults (V110-013)PHASE3 COMPLETED 130Mar 1, 2005May 1, 2005Jan 29, 2015 -
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Immunogenicity
Secondary Endpoints
Safety
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT
Interventions
NameTypeDescription
V110, pneumococcal vaccine polyvalentBIOLOGICAL -
Unlock Study Design Details
Eligibility Criteria
Age Range20 Years — 40 Years
SexALL
Healthy VolunteersYes

Inclusion Criteria: * Males and females in good health, ages 20-40, with no history of pneumococcal vaccination Exclusion Criteria: * Subjects with a recent febrile illness * Known or suspected immune dysfunction, conditions associated with immunosuppression, and receipt of immunosuppressive chem...

Unlock Eligibility Criteria